EMA Authorised: Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) (chenodeoxycholic acid) — Leadiant GmbH

View source ↗

Summary

The EMA authorised Chenodeoxycholic acid Leadiant for Cerebrotedinous xanthomatosis (a rare inborn error of metabolism) with orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebrotendinous Xanthomatosis

Drugs mentioned

• Chenodeoxycholic acid Leadiant (chenodeoxycholic acid)

Snippet

Status: Authorised. Therapeutic area: Xanthomatosis, Cerebrotendinous;Metabolism, Inborn Errors. MAH: Leadiant GmbH. Decision date: 23/07/2025. Orphan medicine